Log in to search using one of your social media accounts:

 

Mylan launches generic version of Gleevec tablets in US
Mylan has launched the generic version of Novartis's Gleevec tablets, Imatinib Mesylate, in 100mg and 400mg versions in the US.   (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 1, 2017 Category: Pharmaceuticals Source Type: news

Imatinib a Double-Edged Sword for Pregnant CML Patients Imatinib a Double-Edged Sword for Pregnant CML Patients
On the one hand, imatinib keeps the CML in check; on the other hand, it carries a risk for fetal congenital malformation if taken during pregnancy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 19, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Imatinib shows increased survival in ICR ’s Phase III oncology trial
A Phase III clinical trial of imatinib (Glivec) conducted by UK researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust demonstrated increased survival in patients with advanced gastrointestinal stromal tumo … (Source: Drug Development Technology)
Source: Drug Development Technology - August 20, 2017 Category: Pharmaceuticals Source Type: news

CML Patients Approach Normal Life Expectancy With Imatinib Treatment
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study. (Source: CancerNetwork)
Source: CancerNetwork - July 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss. Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiter...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news

Survival in Imatinib-Treated CML Independent of Response Time Survival in Imatinib-Treated CML Independent of Response Time
The 10-year survival analysis shows no significant difference in outcomes based on imatinib regimen, including higher dose that has previously been linked to a faster response.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Dasatinib in Children: An Effective Alternative to Imatinib Dasatinib in Children: An Effective Alternative to Imatinib
In children and adolescents with chronic-phase chronic myeloid leukemia, dasatinib shows response rates and safety similar to those seen in adults.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cancer Drug Imatinib May Slow New-Onset Type 1 Diabetes Cancer Drug Imatinib May Slow New-Onset Type 1 Diabetes
"This could one day be a treatment for type 1 diabetes, but this remains very early days," says the researcher.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Jorge E. Cortes, MD Tags: Conferences/ASCO Hematology Chronic Myeloid Leukemia News Videos Hematologic Malignancies Source Type: news

Dasatinib excels in worldwide phase II trial against pediatric CML
(University of Colorado Anschutz Medical Campus) Worldwide phase II clinical trial results presented ASCO 2017 show the promise of the second-generation drug dasatinib against pediatric CML. Of 113 pediatric patients studied, 75 percent of patients who had previously failed or did not tolerate imatinib saw progression-free survival 48 months after starting treatment with dasatinib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 5, 2017 Category: International Medicine & Public Health Source Type: news

KIT Inhibition by Imatinib Helps Severe Refractory Asthma
Improvement in airway hyperresponsiveness seen with imatinib versus placebo (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 22, 2017 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Allergy, Emergency Medicine, Nursing, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

Could Cancer Drug Gleevec Help With Severe Asthma?
Title: Could Cancer Drug Gleevec Help With Severe Asthma?Category: Health NewsCreated: 5/19/2017 12:00:00 AMLast Editorial Review: 5/22/2017 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - May 22, 2017 Category: Respiratory Medicine Source Type: news

Could Cancer Drug Gleevec Help With Severe Asthma?
A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 19, 2017 Category: Consumer Health News Source Type: news

Cancer drug Gleevec may help with severe asthma
A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 19, 2017 Category: Consumer Health News Source Type: news

Could Cancer Drug Gleevec Help With Severe Asthma?
Small study suggests a new approach might one day help those with uncontrolled lung disease (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 19, 2017 Category: Respiratory Medicine Tags: Nursing, Oncology, Pharmacy, Pulmonology, Asthma, Research, News, Source Type: news

Could Cancer Drug Gleevec Help with Severe Asthma?
Small study suggests a new approach might one day help those with uncontrolled lung disease Source: HealthDay Related MedlinePlus Pages: Asthma, Leukemia, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 19, 2017 Category: Consumer Health News Source Type: news

Could Cancer Drug Gleevec Help With Severe Asthma?
FRIDAY, May 19, 2017 -- A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests. Gleevec (imatinib) reduced the " twitchiness " of airways, making them less likely to reflexively constrict when exposed to an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2017 Category: General Medicine Source Type: news

Proof-of principle study finds imatinib improves symptoms for patients with severe asthma
In a new, proof-of-principle study researchers have found that targeting the mast cells with imatinib, a drug used to effectively treat certain forms of cancer, improved airway hyperresponsiveness, a measure of the sensitivity of the airway, and decreased the number of mast cells present in the airway. Treatment also produced a small improvement in airway function. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

Proof-of Principle Study Finds Imatinib Improves Symptoms for Patients with Severe Asthma
In a new, proof-of-principle study, researchers found that targeting the mast cells with imatinib, a drug used to effectively treat certain forms of cancer, improved airway hyper responsiveness, and decreased the number of mast cells present. (Source: BWH News)
Source: BWH News - May 17, 2017 Category: Hospital Management Source Type: news

Novartis misses on rev, tops sales estimates in Q1
Shares in Novartis (NYSE:NVS) rose today after the pharmaceutical company met expectations on Wall Street with its 1st quarter earnings, but missed on sales largely thanks to growing pressure from generics to the company’s top-selling chemotherapy, Gleevec. The company posted profits of $1.92 billion, or 22¢ per share, on sales of $11.53 billion for the 3 months ended March 31, for bottom-line loss of -22% on sales loss of -1% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Novartis misses on rev, tops sales estimates in Q1...
Source: Mass Device - April 25, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: MassDevice Earnings Roundup Optical/Ophthalmic Pharmaceuticals Wall Street Beat Novartis Source Type: news

KIT Mutations Linked to Imatinib Response in GIST KIT Mutations Linked to Imatinib Response in GIST
Different KIT mutations have various associations with the response of gastrointestinal stromal tumors (GISTs) to adjuvant imatinib, according to results from a Scandinavian Sarcoma Group multicenter trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
Source: CancerNetwork - March 29, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Gleevec - A Game Changer?
(MedPage Today) -- The drug has improved survival for the majority of CML patients (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 22, 2017 Category: American Health Source Type: news

New England Journal of Medicine publishes long-term results of Gleevec ®
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. (Source: World Pharma News)
Source: World Pharma News - March 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

​L​eukemia​ drug fends off cancer for a decade, study shows
Gleevec, the brand name for imatinib, "has stood the test of time" with no new safety risks, say cancer experts (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 9, 2017 Category: Consumer Health News Source Type: news

Long-term results of Gleevec ® published
Results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent, have now been published by investigators. According to the National Cancer Institute, prior to Gleevec's 2001 FDA approval, fewer than one in three  CML patients survived five years past diagnosis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 9, 2017 Category: Science Source Type: news

' Imatinib Changed Everything': The Future Is Now More Hopeful'Imatinib Changed Everything': The Future Is Now More Hopeful
The development in the 1990s of this oral drug that targets a driver mutation'fundamentally altered the field of oncology,'says an NEJM editorial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 9, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Title: Gleevec Keeps a Leukemia in Check for More Than a Decade: StudyCategory: Health NewsCreated: 3/8/2017 12:00:00 AMLast Editorial Review: 3/9/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - March 9, 2017 Category: Cancer & Oncology Source Type: news

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there's no evidence of safety concerns linked to long-term use of the drug, researchers say (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - March 9, 2017 Category: Cancer & Oncology Source Type: news

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there's no evidence of safety concerns linked to long - term use of the drug, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 8, 2017 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news

' Imatinib Changed Everything' (CME/CE)
(MedPage Today) -- Legacy confirmed by long-term data from pivotal trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 8, 2017 Category: Hematology Source Type: news

Final Results of Landmark Imatinib Study in CML Show Long-Term Benefit
The final, long-term analysis of the landmark IRIS study showed that imatinib ’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there's no evidence of safety concerns linked to long-term use of the drug, researchers saySource: HealthDay Related MedlinePlus Page: Chronic Myeloid Leukemia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 8, 2017 Category: Consumer Health News Source Type: news

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
WEDNESDAY, March 8, 2017 -- The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment -- with no signs of additional safety risks, a new study finds. Gleevec -- known generically as imatinib -- was hailed as a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 8, 2017 Category: Journals (General) Source Type: news

New England Journal of Medicine publishes long-term results of Gleevec ®
(Oregon Health& Science University) Today the New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. According to the National Cancer Institute, prior to Gleevec's 2001 FDA approval, fewer than one in three   CML patients survived five years past diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 8, 2017 Category: Cancer & Oncology Source Type: news

Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there's no evidence of safety concerns linked to long - term use of the drug, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 7, 2017 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news

Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors
A substantial minority of patients with advanced gastrointestinal stromal tumors (GIST) treated with imatinib mesylate show long-term survival, according to a trial analysis presenting new molecular data.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 21, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Study shows strong long-term survival rates for patients with GIST
Nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years, a new report outlines. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2017 Category: Science Source Type: news

SWOG study shows strong long-term survival rates for patients with GIST
(SWOG) Researchers show that nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years. Results are published in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2017 Category: Global & Universal Source Type: news

Adding Pioglitazone Could Improve Molecular Response in CML Patients
A small preliminary study showed that adding pioglitazone to imatinib therapy might have a favorable impact on residual disease in chronic myeloid leukemia, as measured by conversion to molecular response 4.5. (Source: CancerNetwork)
Source: CancerNetwork - January 5, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Natural Killer Cells Play Role in Ability of CML Patients to Discontinue TKIs
Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib. (Source: CancerNetwork)
Source: CancerNetwork - December 29, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Colombia cuts price of Novartis cancer drug by 44 percent
BOGOTA (Reuters) - Colombia's government has lowered the price of Novartis cancer drug imatinib by nearly half in a bid to cut healthcare costs after failed price negotiations with the Swiss company. (Source: Reuters: Health)
Source: Reuters: Health - December 21, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Retro Report: Lives and Profits in the Balance: The High Stakes of Medical Patents
Tensions inherent to drug pricing pit affordability against the need to recoup investment in research, raising questions about how much of the cost patients should have to bear. (Source: NYT Health)
Source: NYT Health - December 12, 2016 Category: Consumer Health News Authors: CLYDE HABERMAN Tags: Drugs (Pharmaceuticals) Inventions and Patents Prices (Fares, Fees and Rates) Bayh-Dole Act Novartis AG Gleevec Advertising and Marketing Source Type: news

Pfizer blood cancer drug tops standard therapy for untreated patients
(Reuters) - Pfizer Inc said on Monday its cancer drug, Bosulif, was found superior to Novartis AG's Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer characterized by abnormal white blood cells production. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Global Health: Summer Project Turns Into Leukemia Testing Breakthrough
What began as a student effort at a lab in Seattle produced a test for chronic myeloid leukemia that works with a few spots of dried blood on a paper card. (Source: NYT Health)
Source: NYT Health - November 28, 2016 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Tests (Medical) Drugs (Pharmaceuticals) Leukemia Third World and Developing Countries Novartis AG Africa Gleevec Source Type: news

Money in Medicine: Brian Druker on why he gets money from Gilead, not Gleevec
Dr. Brian Druker ’s name is practically synonymous with Gleevec, which is about as close as you can get to a miracle drug. Yet Druker has never directly benefited from Gleevec, which has greatly expanded the life expectancy for those with chronic myeloid leukemia. Because he didn’t invent and patent the drug, h e receives no royalties. He did give a couple of talks about it for drug maker Novartis, but then called it quits on those sorts of gigs. “I decided it was not what I want to be doing,”… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 22, 2016 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

Money in Medicine: Brian Druker on why he gets money from Gilead, not Gleevec
Dr. Brian Druker ’s name is practically synonymous with Gleevec, which is about as close as you can get to a miracle drug. Yet Druker has never directly benefited from Gleevec, which has greatly expanded the life expectancy for those with chronic myeloid leukemia. Because he didn’t invent and patent the drug, h e receives no royalties. He did give a couple of talks about it for drug maker Novartis, but then called it quits on those sorts of gigs. “I decided it was not what I want to be doing,”… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 22, 2016 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

Novartis wins two prestigious Prix Galien Foundation Awards
Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City. (Source: World Pharma News)
Source: World Pharma News - October 31, 2016 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Long-Term Follow-Up Shows Imatinib Discontinuation Remains Safe
The STIM1 study shows that patients with chronic myeloid leukemia who have undetectable minimal residual disease can safely discontinue imatinib therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news

Discovery offers prospect of shorter treatment and cure for chronic myelogenous leukemia
(Dana-Farber Cancer Institute) Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia, patients generally must take them for the rest of their lives and may cease benefiting from them over time. In new research that could suggest a road to cure, scientists have found that CML stem cells die in response to inhibition of a protein called Ezh2. Drugs that target the protein are currently being tested in clinical trials for other cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2016 Category: Cancer & Oncology Source Type: news